Abstract
The article presents the results of researches concerning preventive therapy, relapse treatment and symptomatic treatment of multiple sclerosis, neuromyelitis optica and neuromyelitis optica spectrum disorders. The medicines of first and second line that modulate multiple sclerosis course (modifying medicines) are reviewed. The data about new testing drugs are presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have